DEERFIELD , Ill . , June 26 , and OSAKA , Japan , June 27 , 2009 / PRNewswire / -- Takeda Pharmaceutical Company Limited ( " Takeda " ) today announced that Takeda Global Research & Development Center , Inc . , a wholly owned United States ( U.S. ) subsidiary received on June 26 ( U.S. time ) a complete response letter from the U.S. Food and Drug Administration ( FDA ) regarding the Company 's New Drug Application ( NDA ) for alogliptin , a selective dipeptidyl peptidase IV ( DPP-4 ) inhibitor under investigation for the treatment of type 2 diabetes as an adjunct to diet and exercise .